Article
Biochemistry & Molecular Biology
Theodoros-Ioannis Papadimitriou, Arjan van Caam, Peter M. van der Kraan, Rogier M. Thurlings
Summary: This review examines the relationship between inflammation and fibrosis in systemic sclerosis, as well as the efficacy of current and novel treatment options in reducing fibrosis.
Review
Clinical Neurology
Monica Margoni, Paolo Preziosa, Massimo Filippi, Maria A. Rocca
Summary: Multiple sclerosis is a chronic disease affecting the central nervous system, and recent advancements in immune pathophysiology have led to the identification of selective B-cell-depleting therapies like anti-CD20 monoclonal antibodies, which have shown strong efficacy and safety in treating MS. This has expanded the therapeutic options for both relapsing and progressive MS patients, highlighting the important role of B cells in the disease process.
JOURNAL OF NEUROLOGY
(2022)
Review
Immunology
Andreas Lutterotti, Helen Hayward-Koennecke, Mireia Sospedra, Roland Martin
Summary: Antigen-specific tolerance induction offers personalized treatment for multiple sclerosis by targeting antigens and core pathomechanisms, requiring distinct clinical development approaches. Key aspects include patient selection, outcome measures, demonstrating mechanisms of action, and positioning in the spectrum of MS treatments.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Clinical Neurology
Gavin Giovannoni, Joela Mathews
Summary: Multiple sclerosis is a chronic neurodegenerative disease without a cure. The aim of therapy is to reduce relapse and disability progression. Immune reconstitution therapy (IRT) has become an important treatment option, and cladribine tablets are a selective and effective form of IRT for MS patients. They require fewer treatment courses and monitoring, improving patient adherence.
NEUROLOGY AND THERAPY
(2022)
Review
Multidisciplinary Sciences
Sen Liu, Xu Chen, Tianxin Lin
Summary: This review presents current evidence for enhancing the efficacy of chemotherapy in bladder cancer. The combination of chemotherapy with other treatments, such as targeted therapy and immunotherapy, is discussed. Studies have shown that these combination therapies can improve the response rate and survival of patients receiving chemotherapy. Additionally, potential targets and approaches that may enhance chemosensitivity are explored.
JOURNAL OF ADVANCED RESEARCH
(2022)
Article
Clinical Neurology
Riccardo Garbo, Daniela Cutuli, Simone Lorenzut, Gian Luigi Gigli, Daniele Bagatto, Mariarosaria Valente
Summary: The case study discusses a patient who experienced significant disease activity during the first year of cladribine treatment and was switched to alemtuzumab. Although good control of disease activity was achieved, there were serious infectious complications observed. The results suggest that sequential immune reconstitution therapies may be effective but can lead to higher susceptibility to infections.
FRONTIERS IN NEUROLOGY
(2021)
Article
Medicine, Research & Experimental
Zijian Li, Yongchao Liu, Aili Jia, Yueran Cui, Juan Feng
Summary: This study investigated the changes in the CNS immune microenvironment of MS cases and identified potential therapeutic targets for treatment through in silico data analysis using CIBERSORT.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Review
Clinical Neurology
Jerome De Seze, Laurent Suchet, Claude Mekies, Eric Manchon, Pierre Labauge, Anne-Marie Guennoc, Gilles Defer, Pierre Clavelou, Giovanni Castelnovo, Bertrand Bourre, Caroline Bensa-Koscher, Abdullatif Al Khedr, Julie Le Mao, Lauriane Villemur, Stephane Bouee, Laura Luciani, Patrick Vermersch
Summary: The optimal use of immune reconstitution therapy (IRT) in the management of relapsing multiple sclerosis (RMS) was determined through a Delphi method involving 14 French clinical experts. Consensus was reached on the benefits of early use of IRT, as well as the profiles of patients who could benefit most from this treatment strategy. The expert consensuses provide up-to-date guidance on the use of IRT in clinical practice.
NEUROLOGY AND THERAPY
(2023)
Article
Clinical Neurology
Susana Otero-Romero, Christine Lebrun-Frenay, Saul Reyes, Maria Pia Amato, Magda Campins, Mauricio Farez, Massimo Filippi, Yael Hacohen, Bernhard Hemmer, Rosa Juuti, Melinda Magyari, Celia Oreja-Guevara, Aksel Siva, Sandra Vukusic, Mar Tintore
Summary: This study developed a European consensus on vaccination strategies for people with multiple sclerosis (pwMS) who are candidates for disease-modifying therapies (DMTs). A multidisciplinary working group used formal consensus methodology to formulate recommendations based on the quality of evidence and risk-benefit balance. A total of 53 recommendations were agreed upon, aiming to homogenize immunization practices in pwMS.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Review
Engineering, Biomedical
Mengying He, Tao Yang, Yuhan Wang, Mengyuan Wang, Xingye Chen, Dawei Ding, Yiran Zheng, Huabing Chen
Summary: Immune checkpoint blockade therapy has shown potential efficacy in various cancers, but its effectiveness is limited when used alone. Studies have demonstrated that combining ICBT with other treatment modalities such as chemotherapy, radiotherapy, and phototherapy can enhance therapeutic outcomes. However, there are still challenges and potential issues that need to be addressed in the research on ICBT-based synergistic therapies.
ADVANCED HEALTHCARE MATERIALS
(2021)
Article
Neurosciences
Yan Mi, Jinming Han, Jie Zhu, Tao Jin
Summary: PD-1/PD-L1 signaling plays a crucial role in multiple sclerosis by blocking autoimmune responses, maintaining immune tolerance, and inhibiting autoimmunity. Therefore, PD-1/PD-L1 has the potential to serve as biomarkers or therapeutic targets for multiple sclerosis.
MOLECULAR NEUROBIOLOGY
(2021)
Article
Immunology
Simon Faissner, Neele Heitmann, Carlos Plaza-Sirvent, Paulina Trendelenburg, Ulas Ceylan, Jeremias Motte, Clara Bessen, Doris Urlaub, Carsten Watzl, Oliver Overheu, Anke Reinacher-Schick, Kerstin Hellwig, Stephanie Pfaender, Ingo Schmitz, Ralf Gold
Summary: This study investigated the immune cell alterations and immune response in patients receiving early ofatumumab treatment and compared them to healthy controls following SARS-CoV-2 vaccination. The results showed that ofatumumab treatment led to depletion of B cells and changes in certain T cell subpopulations. The humoral immune response to SARS-CoV-2 was impaired, while the cellular immune response was preserved.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Guillaume Grisay, Julien Pierrard, Caterina Confente, Emmanuel Seront
Summary: Immune checkpoint inhibitors have significantly improved the outcome of patients with urothelial carcinoma, but the diversity of approved agents and limited patient response pose challenges. Current research focuses on exploring new treatment strategies and advancing biomarker development.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Xinda Zhao, Claire Jacob
Summary: All licensed medications for multiple sclerosis (MS) target the immune system, but most drug candidates in human clinical trials have modest or no effects on disease amelioration and remyelination enhancement. Remyelination is a complex process involving multiple cell types, and the interplay between them may differ in humans and rodent models. Successful remyelination requires the regulation of each cell type in a highly organized spatio-temporal manner, making it challenging for drug candidates targeting a single pathway or cell population. Therefore, considering the effects on all CNS cell populations and the optimal time of administration is crucial when exploring new drug candidates for MS.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Anne Wisgalla, Caren Ramien, Mathias Streitz, Stephan Schlickeiser, Andreea-Roxana Lupu, Anke Diemert, Eva Tolosa, Petra C. Arck, Judith Bellmann-Strobl, Nadja Siebert, Christoph Heesen, Friedemann Paul, Manuel A. Friese, Carmen Infante-Duarte, Stefan M. Gold
Summary: During pregnancy, there are significant shifts in NK cell populations, with an increase in CD56(bright) NK cells and a decrease in CD56(dim) NK cells. These changes occur in both pregnant women with multiple sclerosis and healthy pregnant women, potentially contributing to disease amelioration in multiple sclerosis during pregnancy.
FRONTIERS IN IMMUNOLOGY
(2022)
